Commerce Bank Makes New $3.12 Million Investment in Edwards Lifesciences Corporation $EW

Commerce Bank acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, Holdings Channel.com reports. The firm acquired 34,501 shares of the medical research company’s stock, valued at approximately $3,121,000.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in Edwards Lifesciences in the second quarter valued at $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences during the 2nd quarter worth about $1,274,082,000. Norges Bank purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $803,686,000. Deutsche Bank AG acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Mizuho raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Finally, BTIG Research boosted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $90.53 on Tuesday. The stock’s 50-day moving average is $89.30 and its two-hundred day moving average is $84.74. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The firm has a market cap of $52.13 billion, a price-to-earnings ratio of 52.03, a PEG ratio of 2.25 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the business earned $0.67 EPS. The business’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,570 shares of company stock valued at $2,219,390 over the last quarter. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.